Drugs modulating the expression of PD-L1 could represent new therapeutic avenues for the treatment of MM, help potentiate the action of other drugs or be combined to PD-1/PD-L1 inhibitors in order to avoid the potentially problematic combination with immunomodulators. The gene discussed is CD274; the disease is Miyoshi myopathy.